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Abstract
Background: Astrocytes contribute to the crosstalk that generates chronic neuro-inflammation in neurological
diseases; however, compared with microglia, astrocytes respond to a more limited continuum of innate immune
system stimulants. Recent studies suggest that the fibrinolysis system may regulate inflammation. The goal of this
study was to test whether fibrinolysis system components activate astrocytes and if so, elucidate the responsible
biochemical pathway.
Methods: Primary cultures of astrocytes and microglia were prepared from neonatal mouse brains. The ability of
purified fibrinolysis system proteins to elicit a pro-inflammatory response was determined by measuring expression
of the mRNAs encoding tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and chemokine (C-C motif) ligand 2
(CCL2). IκBα phosphorylation also was measured. Plasminogen activation in association with cells was detected by
chromogenic substrate hydrolysis. The activity of specific receptors was tested using neutralizing antibodies and
reagents.
Results: Astrocytes expressed pro-inflammatory cytokines when treated with plasminogen but not when treated
with agonists for Toll-like Receptor-4 (TLR4), TLR2, or TLR9. Microglia also expressed pro-inflammatory cytokines in
response to plasminogen; however, in these cells, the response was observed only when tissue-type plasminogen
activator (tPA) was added to activate plasminogen. In astrocytes, endogenously produced urokinase-type plasminogen
activator (uPA) converted plasminogen into plasmin in the absence of tPA. Plasminogen activation was dependent on
the plasminogen receptor, α-enolase, and the uPA receptor, uPAR. Although uPAR is capable of directly activating cell-
signaling, the receptor responsible for cytokine expression and IκBα phosphorylation response to plasmin was Protease-
activated Receptor-1 (PAR-1). The pathway, by which plasminogen induced astrocyte activation, was blocked by inhibiting
any one of the three receptors implicated in this pathway with reagents such as εACA, α-enolase-specific antibody, uPAR-
specific antibody, the uPA amino terminal fragment, or a pharmacologic PAR-1 inhibitor.
Conclusions: Plasminogen may activate astrocytes for pro-inflammatory cytokine expression through the concerted
action of at least three distinct fibrinolysis protease receptors. The pathway is dependent on uPA to activate plasminogen,
which is expressed endogenously by astrocytes in culture but also may be provided by other cells in the astrocytic cell
microenvironment in the CNS.
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Background
In the CNS, microglia and astrocytes regulate innate im-
munity and neuro-inflammation [1, 2]. By secreting cy-
tokines and other extracellular mediators, these cells
establish crosstalk with one another and with local neu-
rons and also recruit inflammatory cells from the blood.
Microglia express a large continuum of Pattern Recogni-
tion Receptors (PRRs), including diverse members of the
Toll-like Receptor (TLR) family [3, 4]. By contrast, astro-
cytes express a more limited repertoire of PRRs, includ-
ing only low levels of specific TLRs, such as TLR3 [5–7].
Thus, understanding the signals that lead to astrocyte
activation and contribute to neuro-inflammation re-
mains an important problem.
Proteins that function in hemostasis have been impli-
cated in innate immunity and in the regulation of in-
flammation, including Tissue Factor, Fibrinogen, and
Protein C [8–11]. The fibrinolysis system is the arm of
hemostasis that systematically lyses blood clots and
maintains patency in uninjured blood vessels [12]. The
principal activators of fibrinolysis are tissue-type plas-
minogen activator (tPA) and urokinase-type plasmino-
gen activator (uPA), both of which convert plasminogen
(Plg) into plasmin (PM), which degrades fibrin [12, 13].
In recent years, cellular receptors for fibrinolysis prote-
ases and their zymogens have been identified. A family
of structurally diverse but functionally similar receptors
for Plg have been characterized [14]. These receptors,
which in many cases also bind tPA, amplify the rate of
Plg activation, localize PM activity to the outer cell
membrane, and participate in pathways that result in
cell-signaling [14]. The urokinase receptor (uPAR) is a
glycosylphosphatidylinositol (GPI)-anchored receptor
that increases the catalytic efficiency of Plg by uPA and
also associates with transmembrane proteins to form a re-
ceptor complex that signals in response to vitronectin and
uPA [15]. tPA interacts with a distinct receptor complex
that includes the N-methyl-D-aspartate (NMDA) receptor
and Low-Density Lipoprotein Receptor-related Protein-1
(LRP1) to trigger cell-signaling and regulate innate im-
munity [16, 17]. Finally, it has been shown in studies
mainly with monocytes and macrophages that PM directly
cleaves GPCRs in the Protease-activated Receptor (PAR
family) such as PAR-1 and PAR-2 to regulate innate im-
munity [18–21]. Cleavage of PAR-1 by PM also has been
shown in astrocytes [22]. In these cells, PAR-1 cleavage
activates phosphoinositide-3 kinase (PI3K) and induces
expression of transforming growth factor-β3 [22]. The
function of fibrinolysis receptors in astrocytic activation
and their possible effects on neuro-inflammation was the
topic of the current study.
We compared microglia and astrocytes isolated from
mouse pups and showed that both cell types demonstrate
increased expression of pro-inflammatory cytokines,
including TNFα, interleukin-1β (IL-1β), and CCL2 when
treated with Plg. Plg was active in microglial cultures only
when added together with plasminogen activator to gener-
ate PM. By contrast, neonatal mouse astrocytes (N-astro-
cytes), which were not responsive to activators of TLR2,
TLR4, or TLR9, expressed increased levels of cytokines in
response to Plg alone. The responsible pathway required
uPA, which was expressed endogenously by N-astrocytes,
together with a system of fibrinolysis receptors that in-
cluded the Plg receptor, α-enolase, uPAR, and PAR-1.
Despite the well-documented role of uPAR in cell-
signaling [15], including in astrocytes [23], uPAR appar-
ently functioned only to facilitate Plg activation in the
pathway that resulted in pro-inflammatory cytokine ex-
pression. The amino terminal fragment of uPA (ATF),
which replicates most of the cell-signaling activity of uPA
[24–26], functioned as an antagonist of this pathway.
Overall, our results define a multicomponent, linear path-
way, involving three distinct fibrinolysis receptors, that
couples Plg to astrocytic activation. Although in the adult
brain, astrocytes may express decreased levels of uPA,
compared with cultured N-astrocytes, astrocytes also may
become loaded with uPA that is transferred from neurons
[23]. These results suggest novel opportunities for
pharmacological modulation of neuro-inflammation.
Materials and methods
Proteins and reagents
Glu-Plasminogen was purified from human plasma as pre-
viously described [27]. Human tPA, which is produced in
CHO cells and 95% in the two-chain form, was from Mo-
lecular Innovations. Lipopolysaccharide (LPS) serotype 055:
B5 from E. coli was from Sigma-Aldrich. The TLR2 ligand,
lipoteichoic acid (LTA) from S. aureus and the TLR9 lig-
and, ODN 1826, were from InvivoGen. Amiloride (AMD)
was from Sigma-Aldrich. Mouse uPAR-specific antibody
(cat. AF534) and control IgG (cat. AB105C) were from
R&D Systems. α-Enolase-specific polyclonal antibody was
from Invitrogen (cat. 3810T). Rabbit polyclonal antibody
that targets the C-terminus of actin was from Sigma-
Aldrich (cat. A2066). ε-Aminocaproic acid (εACA) was
from MP Biomedicals. Aprotinin was from PanReac Appli-
Chem. SCH 79797 was from Cayman Chemicals. The
plasmin-specific chromogenic substrate, H-D-Val-Leu-Lys-
p-nitroanilide (S-2251) and mouse uPA ATF were from
Molecular Innovations.
Cell culture
Microglia and N-astrocytes were isolated from C57BL/6J
mouse pups [28]. In brief, brains were harvested from
postnatal day 1–6 mice. The cortices were dissected from
the forebrain, and the surrounding meninges were re-
moved. Intact cortices were mechanically and enzymati-
cally dissociated using the Neural Tissue Dissociation Kit
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P (Miltenyi Biotec). Mixed glial cultures were established
in Dulbecco's modified Eagle's medium/F-12 (DMEM/F-
12) supplemented with GlutaMAX (Gibco), 10% fetal bo-
vine serum (FBS, Gibco), and 100 units/ml Antibiotic-
Antimycotic (Gibco). After culturing for 10–14 days,
microglia was harvested by shaking at 200 rpm for 30min
at 37 °C. The floating cells were collected by centrifugation
and re-plated at 3 × 105 cells/well. Oligodendrocytes were
removed by an additional 6 h of shaking. Then, N-
astrocytes were collected by trypsinization and subsequent
centrifugation and re-plated at 3.5 × 105 cells/well on
Poly-D-Lysine hydrobromide-coated wells in DMEM-
High Glucose supplemented with 10% FBS and 100 units/
ml Antibiotic-Antimycotic. Experiments were performed
within 24 h of completing the isolation procedure for
microglia and within 48 h of completing the isolation pro-
cedure for N-astrocytes.
Bone marrow cells were isolated from the femurs of
16-week-old wild-type C57BL/6J male mice, as previ-
ously described [29]. Cells were plated in non-tissue
culture-treated dishes and cultured in DMEM/F-12
medium containing 10% FBS and 20% L929 cell-
conditioned medium for 8 days. Non-adherent cells were
eliminated on day 10. Adherent cells included > 95%
bone marrow-derived macrophages (BMDMs) as deter-
mined by F4/80 and CD11b immunoreactivity. All re-
agents used in this study were tested for their effects on
viability of cells and had no effect as determined by
MTT assay (Invitrogen).
RT-qPCR
In cytokine expression experiments, microglia and N-
astrocytes were cultured in serum-free medium (SFM)
for 30 min and then treated simultaneously for 6 h with
various proteins and reagents, including tPA (12 nM),
Plg (0.2 μM), LPS (0.1 μg/mL), LTA (1.0 μg/mL), ODN
1826 (1.0 μg/mL), aprotinin (33 units/mL), SCH 79797
(2 μM), amiloride (100 μM), uPAR-specific antibody
(1 μg/mL), α-enolase-specific antibody (10 μg/mL),
εACA (10 mM), or the uPA ATF (concentration as indi-
cated). BMDMs were serum-starved for 30 min and then
treated for 3 h with tPA (12 nM) plus Plg (200 nM), LPS
(0.1 μg/mL), LTA (1.0 μg/mL), ODN 1826 (1.0 μM), or
vehicle (20 mM sodium phosphate, 150 mM NaCl, pH
7.4). Total RNA was isolated using the NucleoSpin RNA
kit (Macherey-Nagel) in the presence of DNAse and
reverse-transcribed into cDNA using the iScript cDNA
Synthesis Kit (Bio-Rad). RT-qPCR was performed with
TaqMan gene expression products and an AB Step One
Plus Real-time PCR System (Applied Biosystems). No-
reverse transcriptase controls were performed routinely.
The primer-probe sets were GAPDH (Mm99999915_
g1), RPL13A (Mm01612986_gH), SDHA (Mm01352366_
m1), TNFα (Mm00443258_m1), IL-1β (Mm00434228_
m1), and CCL2 (Mm00441242_m1). The relative change
in gene expression was calculated using the 2−ΔΔCt
method and GAPDH mRNA as a normalizer.
Immunoblot analysis
Microglia and astrocytes were extracted in RIPA buffer
(PBS with 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS) supplemented with Halt Protease and Phos-
phatase Inhibitor Cocktails (Thermo Scientific). The
protein concentration in cell extracts was determined by
DC Protein Assay (Bio-Rad). An equivalent amount of
cellular protein was subjected to SDS-PAGE and
electro-transferred to polyvinylidene fluoride mem-
branes. The membranes were blocked with 5% nonfat
dry milk in 20 mM Tris-HCl, 150 mM sodium phos-
phate, pH 7.4 with 0.1% Tween 20 (TBS-T buffer) and
incubated with primary antibodies from Cell Signaling
Technology, including antibodies that target phospho-
IκBα (Ser32) (1:1000, cat. 2859), IκBα (1:1000, cat. 9242),
and β-actin (1:5000, cat. 3700), followed by horseradish
peroxidase conjugated secondary antibodies (Jackson
ImmunoResearch). Immunoblots were developed using
ProSignal Pico and Femto ECL Reagent substrate (Pro-
metheus) and imaged using the Azure Biosystems c300
imaging system.
PM activity assay
N-astrocytes and microglia were seeded in 48-well plates
(1 × 105 cells/well). Other wells were coated with FBS in
the absence of cells. After 48 h, cells were washed 3
times and the medium replaced with HBSS with Mg+
and Ca2++ (Gibco), 10 mM HEPES and 1mg/mL bovine
serum albumin (BSA), pH 7.4 (H-buffer). Plg, tPA, and/
or amiloride were added as indicated so the final volume
was 180 μL. The concentrations for tPA and amiloride
were 12 nM and 100 μM, respectively. The concentration
of Plg was 0.2 μM. S-2251 (0.2 mM) was added 6 h later.
S-2251 hydrolysis was detected by monitoring the ab-
sorbance at 405 nm as a function of time using a Spec-
traMax M2 microplate reader.
Plg binding to N-astrocytes
Human Glu-Plg was labeled with Alexa Fluor 594 (Invi-
trogen). Labeling reactions were carried out according to
the manufacturer’s instructions. The total reaction mix-
ture was transferred to a BioGelP-30 fine size exclusion
purification resin. PBS was used as an elution buffer to
separate Plg-Alexa Fluor 594 conjugate (Plg-594) from
free dye. Purified Plg-594 was quantified by measuring
the absorbance at 280 nm and 590 nm following manu-
facturer’s instructions. N-astrocytes were plated at 1.3 ×
104 cells/well in 96-well plates in DMEM-high glucose
supplemented with 10% FBS and 100 units/ml
Antibiotic-Antimycotic. The cells were then transferred
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to H-buffer. Plg-594 was incubated with the cells at 4 °C
with gentle agitation for 4 h. Binding studies were per-
formed at 4° to minimize Plg activation, which may be
associated with the generation of new Plg binding sites
[14]. εACA was included in some wells to distinguish
specific and non-specific binding [30]. The cells were
then washed 3 times with H-buffer. Cell-associated Plg-
594 was recovered in PBS plus εACA and quantified by
fluorescent emission at 617 nm using an excitation
wavelength of 590 nm and a cut-off filter of 610 nm in a
SpectraMax M2 microplate reader.
Statistics
Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software Inc.). All results are expressed
as the mean ± SEM. RT-qPCR data were analyzed by
one-way ANOVA followed by Tukey’s multiple compari-
son test (*p < 0.05, **p < 0.01, ***p < 0.001).
Results
N-astrocytes express pro-inflammatory cytokines in
response to Plg but not in response to multiple TLR
ligands
N-astrocytes were treated with 12 nM tPA and 0.2 μM
Plg for 6 h. Control cells were treated with LPS, which
initiates cell-signaling and induces expression of pro-
inflammatory cytokines in a TLR4-dependent manner
[31], LTA, which activates TLR2 [32], or ODN 1826,
which activates TLR9 [33]. RT-qPCR was performed to
assess TNFα mRNA expression. GAPDH mRNA was de-
termined as a normalizer. Figure 1a shows that Plg plus
tPA robustly induced TNFα expression whereas the TLR
agonists failed to have an effect. Similar results were ob-
tained when we studied expression of CCL2 (Fig. 1b)
and IL-1β (Fig. 1c). Because the role of GAPDH as a
RT-qPCR normalizer for astrocytes has been called into
question [34, 35], we repeated these studies using
RPL13A and SDHA as normalizers. Highly similar re-
sults were obtained with both alternatives to GAPDH
(see Additional file 1: Figure S1A–C). In control experi-
ments, we studied mouse BMDMs. In these cells, Plg
plus tPA induced expression of TNFα, as in N-
astrocytes; however, so did all three TLR agonists, prov-
ing that the agonists were active (Fig. 1d).
The response of astrocytes to pro-inflammatory stimuli
also was evaluated by examining IκBα phosphorylation, an
index of NFκB activation [34]. N-astrocytes were treated
with Plg plus tPA, LPS, LTA, or ODN 1826 for 1 h. In re-
sponse to Plg plus tPA, IκBα was phosphorylated and the
total abundance of IκBα was decreased (Fig. 1e), indicating
NFκB activation. Responses were not observed with any of
the TLR agonists. This result was confirmed by densitom-
etry (see Additional file 1: Figure S1D).
Plg activates N-astrocytes independently of exogenously
added tPA
In BMDMs, induction of pro-inflammatory cytokine ex-
pression by Plg requires simultaneous addition of Plg ac-
tivator and generation of catalytically active PM [21]. In
experiments with cultured microglia, the same result
was obtained. TNFα mRNA was robustly increased in
cells treated with Plg plus tPA but not in cell treated
with tPA or Plg alone (Fig. 1)f. The magnitude of the re-
sponse of microglia to Plg plus tPA was similar to that
observed with 0.1 μg/mL LPS, our positive control. IκBα
was phosphorylated and decreased in total abundance in
microglia treated with Plg and tPA but not in cells treated
with tPA or Plg alone (Fig. 1g), again indicating that PM
generation by exogenously added plasminogen activator is
probably required to induce pro-inflammatory cytokine
expression by these cells. The magnitude of the response
to Plg plus tPA in microglia, as determined by densitom-
etry analysis of the IκBα phosphorylation level and the de-
crease in total abundance of IκBα, was similar to that
observed with LPS, as determined by densitometry (see
Additional file 1: Figure S1E).
When N-astrocytes were treated with 200 nM Plg plus
12 nM tPA or with Plg in the absence of tPA for 6 h,
TNFα mRNA expression was increased (Fig.1h). The
magnitude of the effect was equivalent in the presence
or absence of tPA. tPA alone failed to increase TNFα ex-
pression by N-astrocytes. Similar results were obtained
when we studied expression of CCL2 (Fig. 1i) and IL-1ß
(Fig. 1j). Again, expression of these pro-inflammatory cy-
tokines was increased comparably by Plg plus tPA or by
Plg alone. In the absence of Plg, tPA did not regulate ex-
pression of IL-1β or CCL2.
When N-astrocytes were treated with 0.2 μM Plg plus 12
nM tPA or with 0.2 μM Plg in the absence of tPA for 1 h,
IκBα was phosphorylated and the total abundance of IκBα
was decreased (Fig. 1k). tPA did not cause IκBα phosphor-
ylation in the absence of Plg. This result was confirmed by
densitometry (see Additional file 1: Figure S1F). Figure 1 l
shows that in response to Plg, IκBα was phosphorylated
gradually as a function of time, beginning at 45min (see
also Additional file 1: Figure S1G). This result is consistent
with a model in which the Plg must be modified to initiate
cell-signaling, for example by endogenously produced plas-
minogen activators.
N-astrocytes activate Plg endogenously
To test whether N-astrocytes express endogenous plas-
minogen activators that allow Plg activation, we incu-
bated 0.2 μM Plg with N-astrocytes, with microglia, and
in wells without cells. In some wells, we added 12 nM
tPA. After 6 h, PM was detected by measuring the rate
of hydrolysis of S-2251. In N-astrocyte cultures, similar
levels of PM were detected irrespective of whether tPA
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Fig. 1 Plg induces expression of cytokines independently of tPA in N-astrocytes a–c N-astrocytes were serum-starved for 30min and then treated for 6 h
with plasminogen (Plg, 0.2 μM) plus tPA (12 nM), lipopolysaccharide (LPS, 0.1 μg/mL), lipoteichoic acid (LTA, 1.0 μg/mL) or oligodeoxynucleotides (ODN,
1 μM). Expression of the mRNAs encoding TNFα, IL-1β and CCL2 was determined (mean ± SEM; n = 3; ***p < 0.001; one-way ANOVA with Tukey’s post
hoc test. Statistical analysis is relative to the vehicle control). d BMDMs were treated for 3 h with Plg plus tPA, LPS, LTA or ODN. RT-qPCR was performed to
compare mRNA levels for TNFα (mean ± SEM; n = 3; ***p < 0.001, **p < 0.01; one-way ANOVA with Tukey’s post hoc test). The presented results show the
“fold increase” in mRNA expression compared with cultures treated with vehicle. e Serum-starved N-astrocytes were treated for 1 h with Plg plus tPA, LPS,
LTA (1.0 μg/mL), (1 μM), or vehicle. Equal amounts of cellular protein (30 μg) were subjected to immunoblot analysis to detect phospho-IκBα, IκBα and β-
actin. f Microglia were serum-starved for 30min and then treated for 6 h with Plg (0.2 μM), Plg plus tPA (12 nM), LPS (0.1 μg/mL) or vehicle. RNA was
isolated and RT-qPCR was performed to determine TNFαmRNA (mean ± SEM; n = 3; ***p < 0.001; one-way ANOVA with Tukey’s post hoc test. Statistical
analysis is relative to the vehicle control). g Microglia were incubated for 1 h with Plg (0.2 μM), Plg plus tPA (12 nM), or LPS (0.1 μg/mL). Immunoblot
analysis was performed to determine phospho-IκBα, total IκBα and β-actin. h–j N-astrocytes were serum-starved for 30min and then treated with tPA
alone (12 nM), Plg (0.2 μM) alone, or tPA plus Plg for 6 h. Expression of the mRNAs encoding TNFα, IL-1β, and CCL2 was determined (mean ± SEM; n = 3;
***p < 0.001; one-way ANOVA with Tukey’s post hoc test. Statistical analysis is relative to the vehicle control). k N-astrocytes were incubated for 1 h with
tPA (12 nM), Plg (0.2 μM), or with tPA plus Plg. Immunoblot analysis was performed to detect phospho-IκBα, IκBα and β-actin. l N-astrocytes were treated
with Plg (0.2 μM) for the indicated times. Immunoblot analysis was performed to detect phospho-IκBα, IκBα, and β-actin
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was added or not (Fig. 2a). By contrast, in wells with
microglia, PM was detected only when tPA was added
together with Plg. The same was true in wells without
cells.
To confirm that Plg-induced cytokine expression in
N-astrocytes requires PM generation, we treated N-
astrocytes with Plg alone or Plg plus tPA for 6 h in the
presence or absence of the plasmin active site inhibitor,
aprotinin. Figures 2 b–d show that aprotinin blocked the
effects of Plg and Plg plus tPA on expression of TNFα,
IL-1β, and CCL2 by N-astrocytes. Aprotinin also blocked
the ability of Plg and Plg plus tPA to induce IκBα phos-
phorylation in N-astrocytes (Fig. 2e, Additional file 1:
Figure S1H).
Plg receptors are necessary for induction of cytokine
expression by Plg
Plg receptors amplify the rate of Plg activation by tPA
and uPA [14]. These receptors also may be involved in
cell-signaling pathways activated by Plg [21, 35]. Because
Plg receptor interactions are dependent on Plg lysine-
binding sites, these interactions are competitively inhib-
ited by εACA [30]. Figure 3a shows that N-astrocytes
bound fluorescently labeled Plg (Plg-594) in a specific
manner, when specific binding was defined by the frac-
tion of bound Plg displaced by εACA. The KD for spe-
cific binding of Plg-594 to N-astrocytes was 1.0 ±
0.3 μM, consistent with the known binding affinity of Plg
to Plg receptors in other cell types [14]. When N-
Fig. 2 Plg activation is required for induction of cytokine expression by N-astrocytes. a Plg (0.2 μM), Plg plus tPA (12 nM) or vehicle was added to
wells with N-astrocytes, microglia, or no cells for 6 h. Then, S-2251 (0.2 mM) was added. The velocity of S-2251 hydrolysis was determined ΔAbs
405 nm/min × 103 (mean ± SEM, n = 3; **p < 0.01; *p < 0.1 one-way ANOVA with Tukey’s post hoc test. Statistical analysis is relative to the
vehicle control). b–d N-astrocytes were treated for 6 h with Plg (0.2 μM), Plg plus tPA (12 nM) or vehicle, with and without Aprotinin (33 units/ml).
RT-qPCR was performed to determine TNFα, IL-1β, and CCL2 mRNA (mean ± SEM; n = 3; ***p < 0.001, **p < 0.01; one-way ANOVA with Tukey’s
post hoc test. Statistical analysis is relative to the vehicle control). e N-astrocytes were treated with Plg (0.2 μM), Plg plus tPA (12 nM), or vehicle in
presence and absence of Aprotinin (33 units/ml) for 1 h. Immunoblot analysis was performed to detect phospho-IκBα, IκBα, and β-actin
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astrocytes were incubated with Plg alone or with Plg
plus tPA, in the presence of εACA, expression of TNFα,
IL-1β, and CCL2 were blocked (Fig. 3b–d). These results
suggest that Plg receptors are required for Plg activation
and for induction of pro-inflammatory cytokine expres-
sion by PM in N-astrocytes.
The molecular nature of Plg receptors varies from cell
type to cell type. In many cell types, α-enolase, which is
typically an intracytoplasmic protein, translocates to the
cell surface and functions as a Plg receptor [36–38]. Like
α-enolase, actin may translocate to the astrocyte cell-
surface and has been reported to bind Plg and amplify
Fig. 3 Plg receptors are required for induction of cytokine expression in N-astrocytes by Plg. a Specific binding of Plg-594 to N-astrocytes. The
presented graph shows total binding, binding in the presence of εACA (non-specific), and specific binding, which is defined as binding that is
displaced by εACA (mean of three separate binding studies). b–d N-astrocytes were treated with Plg (0.2 μM), Plg plus tPA (12 nM) or vehicle, in
the presence or absence of 10 mM εACA for 6 h. RT-qPCR was performed to determine TNFα, IL-1β and CCL2 mRNA (mean ± SEM; n = 3; ***p <
0.001, **p < 0.01; one-way ANOVA with Tukey’s post hoc test. Statistical analysis is relative to the vehicle control). e–g N-astrocytes were treated
with Plg (0.2 μM), Plg plus tPA (12 nM) or vehicle, in the presence of 10 μg/mL α-enolase-specific antibody, antibody that targets the Plg-binding
site in actin (25 nM), or non-specific IgG for 6 h. RT-qPCR was performed to determine TNFα, IL-1β, and CCL2 mRNA. The ability of each antibody
to inhibit cytokine expression in response to the eliciting agent (% inhibition) is shown (mean ± SEM; n = 4; **p < 0.01, *p < 0.05; two-way
ANOVA with Tukey’s post hoc test). (h) N-astrocytes were treated with Plg (0.2 μM), Plg plus tPA (12 nM), or vehicle in presence and absence of α-
enolase-specific antibody (10 μg/mL) for 1 h. Immunoblot analysis was performed to detect phospho-IκBα, IκBα, and β-actin
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Plg activation [39]. Figures 3 e–g show that, in N-
astrocytes, α-enolase-specific antibody completely blocked
expression of TNFα, IL-1β, and CCL2 in response to Plg
or Plg plus tPA. Actin-specific antibody, by contrast, failed
to inhibit cytokine expression. Non-specific IgG, at
equivalent concentrations, also was without effect. α-
enolase-specific antibody blocked the ability of Plg and Plg
plus tPA to induce IκBα phosphorylation in N-astrocytes
(Fig. 3h, Additional file 1: Figure S1I), supporting the re-
sults of our cytokine expression studies.
PM induces inflammatory cytokine expression in N-
astrocytes via a PAR-dependent pathway
PAR-1, a G-protein-coupled receptor that is activated by
proteolytic cleavage, is strongly expressed in resting as
well as reactive astrocytes and plays a key role in the astro-
cytic response to injury in vivo [40, 41]. To test whether
PARs are involved in the pathway by which Plg induces
cytokine expression in N-astrocytes, we treated these cells
with the selective PAR-1 antagonist, SCH 79797. SCH
79797 completely blocked expression of TNFα, IL-1β, and
CCL2 in response to Plg or Plg plus tPA (Fig. 4a–c). SCH
79797 also blocked IκBα phosphorylation when N-
astrocytes were treated with Plg or Plg plus tPA for 1 h
(Fig. 4d, Additional file 1: Figure S1J).
Endogenously expressed uPA and uPAR are required for
Plg-induced cytokine expression by N-astrocytes
AMD is a specific inhibitor of uPA enzymatic activity
that does not affect the activity of tPA [42]. To identify
the plasminogen activator expressed by N-astrocytes and
responsible for converting Plg into an astrocyte-
activating agent, cells were incubated with Plg, Plg plus
tPA, or vehicle in presence or absence of AMD. AMD
blocked expression of TNFα, IL-1β, and CCL2 in N-
astrocytes treated with Plg alone, but not in cells treated
with Plg plus tPA (Fig. 5a–c). These results suggest that
the endogenous Plg activator in N-astrocytes is uPA. In
IκBα phosphorylation studies, AMD had the same effect,
inhibiting the response to Plg alone but not to Plg plus
tPA (Fig. 5d, Additional file 1: Figure S1K).
uPAR promotes Plg activation by uPA and also dir-
ectly triggers cell-signaling in response to uPA [15]. To
test whether uPAR is necessary in the pathway by which
Fig. 4 PAR-1 is essential in the pathway by which PM activates N-
astrocytes. (a–c) N-astrocytes were treated with Plg (0.2 μM), Plg plus
tPA (12 nM) or vehicle in presence and absence of SCH 79797 (2 μM)
for 6 h. RT-qPCR was performed to determine expression of TNFα, IL-
1β, and CCL2 (mean ± SEM; n = 3; ***p < 0.001; one-way ANOVA
with Tukey’s post hoc test. Statistical analysis is relative to the
vehicle control). d N-astrocytes were treated with Plg (0.2 μM), Plg
plus tPA (12 nM), or with vehicle, in the presence and absence of
SCH 79797 (2 μM) for 1 h. Immunoblot analysis was performed to
detect phospho-IκBα, IκBα, and β-actin
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Plg induces pro-inflammatory cytokine expression by N-
astrocytes, we treated N-astrocytes with Plg alone, Plg
plus tPA, or vehicle in the presence of uPAR-specific
antibody or non-specific IgG. uPAR-specific antibody
neutralized the effects of Plg on expression of TNF-α,
IL-1β, and CCL2 but did not inhibit cytokine expression
in response to Plg plus tPA (Fig. 6a–c). Non-specific IgG
was without effect. uPAR-specific antibody also inhibited
IKBα phosphorylation selectively in response to Plg
alone but not Plg plus tPA (Fig. 6d, Additional file 1:
Figure S1L). Thus, uPAR plays an essential role in the
pathway by which Plg stimulates pro-inflammatory cyto-
kine expression in N-astrocytes in the absence of ex-
ogenously added Plg activator.
The uPA ATF inhibits Plg-induced N-astrocyte activation
The uPA ATF binds to uPAR, similarly to full-length
uPA, and reproduces the signaling responses elicited
when uPA binds to uPAR [24–26]. To determine
whether uPAR functions in promoting Plg-induced cyto-
kine expression by N-astrocytes by facilitating Plg activa-
tion or through uPAR-initiated cell-signaling, we treated
N-astrocytes with Plg in the presence of increasing con-
centrations of uPA ATF. Figures 7 a–c show that the
uPA ATF inhibited the effects of Plg on expression of
TNFα, IL-1β, and CCL2; the activity of the uPA ATF
was ATF-concentration-dependent. The uPA ATF also
inhibited IκBα phosphorylation in N-astrocytes in re-
sponse to Plg (Fig. 7d, Additional file 1: Figure S1M).
These results suggest that the principal activity of uPAR
is to facilitate Plg activation by endogenously produced
uPA and not to trigger cell-signaling. uPA ATF probably
functions by competitively displacing uPA from uPAR,
which disrupts the Plg activation receptor complex.
Discussion
Neuro-inflammation is increasingly recognized as an im-
portant regulator of diverse neurological diseases, including
multiple sclerosis, Alzheimer’s disease, other forms of neu-
rodegeneration, traumatic brain injury, ischemic stroke, and
central sensitization in pain processing [1, 2, 43–46]. While
the role of microglia in neuro-inflammation is well recog-
nized, astrocytes also are major contributors, especially in
Fig. 5 a–d N-astrocytes produce uPA to activated Plg
endogenously. N-astrocytes were treated for 6 h with Plg (0.2 μM),
Plg plus tPA (12 nM), or vehicle in the presence or absence of
amiloride (AMD, 100 μM). RT-qPCR was performed to determine
mRNA levels for TNFα, IL-1β, and CCL2 (mean ± SEM; n = 3; ***p <
0.001, **p < 0.01; one-way ANOVA with Tukey’s post hoc test). d N-
astrocytes were treated with (0.2 μM), Plg plus tPA (12 nM), or
vehicle in presence and absence of amiloride (100 μM) for 1 h.
Immunoblot analysis was performed to detect phospho-IκBα, IκBα,
and β-actin
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chronic CNS inflammatory states, despite their more lim-
ited repertoire of TLRs and other PRRs [1, 2, 5, 6].
There is considerable evidence that activation of fi-
brinolysis may contribute to neuro-inflammation. When
LPS is injected into the hippocampus of Plg gene knock-
out mice, the inflammatory response within the brain is
attenuated [47]. In experimental autoimmune enceph-
alomyelitis (EAE), an accepted model of multiple scler-
osis, Plg gene knock-out mice develop delayed disease of
lesser severity [48]. Furthermore, depleting Plg outside
the CNS, using antisense oligonucleotide (ASO) tech-
nology, decreases the severity of pathology in a mouse
model of Alzheimer’s Disease [49]. In this latter
study, complex mechanisms may be operational be-
cause the ASO approach does not appear to affect
Plg levels within the CNS. Although Plg is expressed
mainly by the liver, other cells and tissues, including
CNS cells, express Plg [50].
The role of uPA and uPAR in neuro-inflammation ap-
pears more context-specific. Expression of uPA in the
CNS is increased in neuro-inflammation [51]. Further-
more, in ischemic brain injury, binding of uPA expressed
by neurons to astrocytic uPAR results in uPAR-initiated
cell-signaling and astrocytic activation [23]. However,
uPA and uPAR appear to be protective in EAE [52], as
opposed the exacerbating role that would be predicted if
the major role of uPA and uPAR is Plg activation [48].
The results presented herein demonstrate that PM
generation induces expression of the potently pro-
inflammatory cytokines, TNFα, IL-1β, and CCL2, in
microglia and astrocytes. In N-astrocytes, the pathway
by which Plg increases cytokine expression is tightly
controlled by a series of fibrinolysis receptors, including
the Plg receptor, α-enolase, uPAR, and PAR-1. α-enolase
and uPAR appear to function mainly to amplify Plg acti-
vation, implicating PAR-1 as the major signal transduc-
tion initiator. The ability of the ATF to block cytokine
expression by Plg in N-astrocytes, suggests that uPAR-
initiated cell-signaling is not sufficient in and of itself to
activate these astrocytes. Our results with the uPA ATF
do not rule out the possibility that when N-astrocytes
produce uPA endogenously, uPAR-associated uPA has
the dual role of promoting Plg activation, which is essen-
tial for cytokine induction, and triggering uPAR signal-
ing, which may regulate the degree of astrocytic
activation, as previously observed [23]. Figure 8 presents
a model showing how three distinct fibrinolysis recep-
tors work in concert to promote astrocytic activation in
response to Plg. Multiple targets for antagonizing this
pathway are identified.
N-astrocytes differed from microglia in culture and
from cultured BMDMs, studied previously [21], in that
Plg-induced cytokine expression independently of ex-
ogenously added Plg activator. This result reflects the
Fig. 6 uPAR-specific antibody neutralizes the effects of Plg on cytokine expression by N-astrocytes. (a–c) N-astrocytes were treated with Plg
(0.2 μM), Plg plus tPA (12 nM), or vehicle in presence and absence of uPAR-specific antibody (1 μg/mL) or an equivalent concentration of non-
specific IgG for 6 h. Expression of TNFα, IL-1β, and CCL2 was determined by RT-qPCR (mean ± SEM; n = 3; ***p < 0.001; one-way ANOVA with
Tukey’s post hoc test. Statistical analysis is relative to the vehicle control). d N-astrocytes were treated with Plg (0.2 μM), Plg plus tPA (12 nM) or
vehicle in presence and absence of uPAR-specific antibody (1 μg/mL) or an equivalent concentration of non-specific IgG. Immunoblot analysis
was performed to detect phospho-IκBα, IκBα and β-actin
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ability of N-astrocytes in culture to express uPA and ac-
tivate Plg in the absence of added tPA. In intact brain,
astrocytic expression of uPA may be highest during de-
velopment and then decrease [53]. However, in a tissue,
as opposed to cell culture, astrocytic uPAR has the cap-
acity to ligate uPA derived from any cell type in the cel-
lular microenvironment. Thus, in various forms of
pathology, the pathway described here may become op-
erational due to astrocytic loading of uPAR with uPA
produced by other cell types such as uPA [23].
N-astrocytes also differed from microglia and cultured
BMDMs in that these cells demonstrated limited respon-
siveness to TLR agonists. In our studies, N-astrocytes
failed to express increased levels of pro-inflammatory cy-
tokines in response to agonists for TLR2, TLR4, and
TLR9. Farina et al. showed that human astrocytes ex-
press TLR3 [7]. These same investigators were unable to
demonstrate astrocytic expression of TLR2, TLR4, or
TLR9. However, others have shown that expression of
some TLRs may be increased when astrocytes are acti-
vated [54, 55]. Understanding how the activity of well
described pattern recognition receptors and fibrinolysis
receptors are integrated in the function of astrocytes in
innate immunity is an important topic for future work.
LDL Receptor-related Protein-1 (LRP1) is a tPA recep-
tor not studied here; however, its activity in promoting
tPA endocytosis by astrocytes is previously reported
[56]. Based on its ability to clear tPA from the astrocytic
cell-surface, LRP1 has the capacity to regulate the amount
of tPA available for Plg activation. LRP1 also may regulate
the abundance of cell-surface uPAR via endocytosis [57].
Either of these mechanisms may regulate astrocytic activa-
tion and expression of pro-inflammatory cytokines by as-
trocytes in vivo.
Our results identifying α-enolase and not actin as a
cell-surface Plg receptor in astrocytes contrast with pre-
vious results supporting a role for actin [39]. An import-
ant difference in the two studies; however, may be the
major plasminogen activator considered. In the previous
study, actin was identified as essential in promoting Plg
activation by tPA. In the pathway by which Plg leads to
cytokine expression, studied here, uPA appeared to be
the essential Plg activator. Although actin-specific anti-
body did not inhibit cytokine expression in our
Fig. 7 The uPA ATF blocks cytokine expression by N-astrocytes in
response to Plg. a–c N-astrocytes were treated for 6 h with Plg
(0.2 μM) and the indicated concentrations of uPA ATF. Expression of
TNFα, IL-1β, and CCL2 was determined by RT-qPCR (mean ± SEM; n
= 3; ***p < 0.001; one-way ANOVA with Tukey’s post hoc test.
Statistical analysis is relative to the vehicle control). d N-astrocytes
were treated for 1 h with Plg (0.2 μM) and the indicated
concentrations of uPA ATF. Immunoblot analysis was performed to
detect phospho-IκBα, IκBα, and β-actin
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experiments in which cells were treated with Plg plus
tPA, it is still possible that distinct Plg receptors function
in astrocytes to promote Plg activation by tPA or uPA.
PAR-1 is best known for its function as a thrombin re-
ceptor, which informs cells that coagulation has been ac-
tivated; however, PAR-1 is proteolytically activated by
other proteases as well, including plasmin [58, 59]. In
monocytes and macrophages, PM-mediated PAR cleav-
age is pro-inflammatory [18–21]. We concluded that a
PAR and probably PAR-1 is the ultimate signal trans-
ducer responsible for the response to PM in N-astrocytes
based on studies with the PAR-1-specific inhibitor, SCH
79797. This reagent completely blocked expression of
TNFα, IL-1β, and CCL2 in response to Plg. PAR-1 may be
a target for inhibiting neuro-inflammation. Because the
pathway by which Plg causes pro-inflammatory cytokine
expression by N-astrocytes is linear, in addition to PAR-1,
the other two required fibrinolysis receptors in this path-
way, α-enolase and uPAR, also may be targets for inhibit-
ing the activity of PM. The effectiveness of targeting
uPAR was demonstrated here in studies with uPAR-
specific antibody and the uPA ATF. Hypothetically, op-
posing astrocytic activation may attenuate the crosstalk
with microglia and other CNS cells, which adds to the
chronicity of inflammation.
Conclusions
In the CNS, activation of astrocytes leads to crosstalk with
cells such as microglia and contributes to chronic neuro-
inflammation. Compared with microglia, astrocytes express
a less robust continuum of Pattern Recognition Receptors.
We describe a pathway by which the zymogen form of the
fibrinolysis protease, plasminogen, causes astrocytic activa-
tion and expression of pro-inflammatory cytokines, includ-
ing TNF-α, IL-1β, and CCL2. The pathway requires a series
of receptors for fibrinolysis proteins, including α-enolase,
uPAR, and PAR-1. Targeting any of these receptors on as-
trocytes blocked the pro-inflammatory activity of plasmino-
gen. Fibrinolysis protease receptors may be targets for
inhibiting neuro-inflammation.
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